• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by BeiGene

    < Previous 1 2 3 Next >
    BeiGene Enters Next Phase of Global Growth with Announcement of Second Quarter 2024 Financial Results and Corporate Updates
    From BeiGene
    Via Business Wire
    Tickers BGNE
    First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
    From BeiGene
    Via Business Wire
    Tickers BGNE
    BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) in Relapsed or Refractory Follicular Lymphoma
    From BeiGene
    Via Business Wire
    Tickers BGNE
    BeiGene to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
    From BeiGene
    Via Business Wire
    Tickers BGNE
    BeiGene Announces Positive CHMP Opinion for Tislelizumab as a Treatment for Advanced or Metastatic ESCC
    From BeiGene
    Via Business Wire
    Tickers BGNE
    BeiGene Announces FDA Acceptance of sNDA for Fifth BRUKINSA® Indication
    From BeiGene
    Via Business Wire
    Tickers BGNE
    BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors
    From BeiGene
    Via Business Wire
    Tickers BGNE
    BeiGene to Host Investor Research and Development Day in Person and via Webcast on July 18, 2023
    From BeiGene
    Via Business Wire
    Tickers BGNE
    BeiGene to Vigorously Defend Patent Infringement Allegations by Pharmacyclics
    From BeiGene
    Via Business Wire
    Tickers BGNE
    BeiGene Highlights Promising Data from Blood Cancer Portfolio and Pipeline at the European Hematology Association Hybrid Congress
    From BeiGene
    Via Business Wire
    Tickers BGNE
    BeiGene Presentations at the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio
    From BeiGene
    Via Business Wire
    Tickers BGNE
    BeiGene to Present at Upcoming Investor Conferences
    From BeiGene
    Via Business Wire
    Tickers BGNE
    The Max Foundation, BeiGene, and the BeiGene Foundation Announce Collaboration to Advance Health Equity by Providing Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries
    From BeiGene
    Via Business Wire
    Tickers BGNE
    BeiGene Receives New Approvals for BRUKINSA® (zanubrutinib) in China
    From BeiGene
    Via Business Wire
    Tickers BGNE
    BeiGene to Highlight Broad Oncology Portfolio at the 2023 ASCO Annual Meeting
    From BeiGene
    Via Business Wire
    Tickers BGNE
    BeiGene Announces Goals Focused on Sustainable Growth and Workforce Diversity in New ESG Report
    From BeiGene
    Via Business Wire
    Tickers BGNE
    BeiGene Announces Positive Phase 3 Tislelizumab Trial in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
    From BeiGene
    Via Business Wire
    Tickers BGNE
    MapKure, BeiGene and SpringWorks Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023
    From BeiGene
    Via Business Wire
    Tickers BGNE
    BeiGene Expands Presence in Latin America With Opening of Brazil Office
    From BeiGene
    Via Business Wire
    Tickers BGNE
    BeiGene Appoints Julius Pryor III as First Global Head of Diversity and Health Equity
    From BeiGene
    Via Business Wire
    Tickers BGNE
    BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey
    From BeiGene
    Via Business Wire
    Tickers BGNE
    BeiGene Receives 10th Approval for PD-1 Inhibitor Tislelizumab in China
    From BeiGene
    Via Business Wire
    Tickers BGNE
    BeiGene to Present at Cowen’s 43rd Annual Healthcare Conference
    From BeiGene
    Via Business Wire
    Tickers BGNE
    New Talk About It Resources Aim to Accelerate Integration of Mental Health into Quality Cancer Care
    From BeiGene
    Via Business Wire
    Tickers BGNE
    BeiGene to Present at Upcoming Investor Conferences
    From BeiGene
    Via Business Wire
    Tickers BGNE
    BRUKINSA® Approved in the U.S. for Chronic Lymphocytic Leukemia
    From BeiGene
    Via Business Wire
    Tickers BGNE
    BRUKINSA® (zanubrutinib) Receives Marketing Authorization for Chronic Lymphocytic Leukemia (CLL) and Marginal Zone Lymphoma (MZL) in Great Britain by MHRA
    From BeiGene
    Via Business Wire
    Tickers BGNE
    BeiGene Announces Expansion of Coverage on China’s National Reimbursement Drug List
    From BeiGene
    Via Business Wire
    Tickers BGNE
    BeiGene Presents New Research from Tislelizumab Global Development Program at 2023 ASCO Gastrointestinal Cancers Symposium
    From BeiGene
    Via Business Wire
    Tickers BGNE
    BeiGene to Present at the J.P. Morgan 41st Annual Healthcare Conference
    From BeiGene
    Via Business Wire
    Tickers BGNE
    < Previous 1 2 3 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.